High Throughput Screening (HTS): A Global Strategic Business Report
San Jose, California (PRWEB) March 13, 2012
Follow us on LinkedIn – As a drug discovery technology, high throughput screening or HTS, is a process wherein target molecules are tested against batches of drug candidate compounds. The technology helps in accelerating the drug discovery process, a critical requirement for pharmaceutical companies operating in a competitive marketplace. The importance of speeding up time to market can be put into perspective by the fact that companies first to market a drug can generate massive revenues, strengthen competitive advantages and corner an assured large market share for the lifetime of the drug. High throughput screening gives companies the advantage of high throughput and low volumes in the initial and crucial stages of drug discovery. A shortened drug discovery cycle also offers researchers the opportunity for skimming the market and optimizing revenue generation and HTS is aimed at exactly this. HTS also increases the chances of fast track clinical trial clearings as it addresses the issues of animal toxicity, pharmacokinetics and side effects. Years of refining technology developments have made modern day HTS systems capable of screening large libraries of compounds at a rapid rate.
Growing number of potential drug targets is directly benefiting the market for HTS. Advances in genomic and proteomics research technologies have, over the decades, resulted in increased number of potential drug targets for screening by means of high throughput screening (HTS). Increased deployment of effective tools such as protein arrays and DNA microarrays in research is also helping in the identification of a large number of drug candidates for further evaluation and screening through HTS, thereby widening the latter’s scope and usage. In addition, increased injection of funds by pharmaceutical and biotech companies into supporting high voltage R&D projects is largely enthused by the unmet and untapped potential for newer, more effective drugs and treatments. The rapidly aging world population will offer even greater opportunities going forward.
HTS success rates are largely dependent upon the “quality of compound library’ and ‘selection of targets. At a time when kinases and G-protein Coupled Receptors (GPCRs) are expanding spectrum and when biochemical assays are sharing limelight with cell based screening, better target validation becomes a real challenge. Technology maturity has helped push costs down making HTS affordable by smaller companies and academia. With increased availability of instrumentation, shared compound libraries and bioinformatics software, even smaller companies can afford HTS systems, changing the paradigm of HTS. In the upcoming years, growth in the market will be driven by demand expansion of HTS instrumentation from large pharmaceutical companies to smaller companies and start-ups. Further, academia has also entered the HTS arena, which was hitherto the exclusive domain of the pharmaceutical industry. Consequently, a large number of small molecule library syntheses are being contracted to university laboratories. Using HTS as a major tool, academia is all set to take drug discovery to new heights.
Technology innovations will continue to hog the limelight in the marketplace. Key technology areas poised to influence HTS include miniaturization, target selection, label-free applications, innovations in cell culture, high content screening, and compound libraries expansion. As stated by the new market research report on High Throughput Screening, the United States dominates the world market. Europe is forecast to emerge into the fastest growing individual regional market with a projected CAGR of 11.9% over the analysis period.
Major players in the marketplace include Agilent Technologies Inc., Aurora Biomed Inc., Axxam SpA, BioFocus DPI Ltd., BMG LABTECH GmbH, Caliper Life Sciences, Corning Inc., DiscoveRx Corporation, EVOTEC BioSystems, Genedata AG, IntelliCyt Corporation, Luminex Corporation, Life Technologies Corporation, MatriCal Bioscience, PerkinElmer Inc., Roche Applied Sciences, and Sigma-Aldrich Corporation, among others.
The research report titled “High Throughput Screening (HTS): A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of industry and product overview, current market trends, drivers & issues, HTS technologies, drug discovery market, technological developments, recent industry activity and profiles of market players worldwide. Market estimates and projections is provided in (US$) for major geographic markets such as US, Canada, Japan, Europe and Rest of World.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/